Soon, a gene test to help patients in fighting bowel cancerJune 3rd, 2008 - 5:20 pm ICT by ANI
Melbourne , June 3 (ANI): Australian oncologists have made a major breakthrough that would enable a gene test to predict how bowel cancer patients would react to the current drug therapies.
The researchers conducted an international trail, which involved 587 people, including patients at six Australian centres and identified a type of gene that has become the first marker of bowel cancer.
Bowel cancer kills about 80 Australians every week and researchers found that the latest anti-cancer drugs, Erbitux, along with standard chemotherapy, may help individuals with their cancer in advanced disease and who have the “normal” form of the gene, i.e. about two-thirds of sufferers,
On the other hand, the remaining one third whose tumours contained the mutant form of the gene, did not benefit at all from adding the new drug.
Thus, it will now be possible to apply a genetic test to show who could be helped from having the expensive therapy, which is not yet listed on the Pharmaceutical Benefits Scheme.
“This is a big step forward in personalised medicine which is targeted to suit an individual person’s disease. It’s better for patients because they don’t get treatments that don’t work, and the Government will like it too because it makes this costly drug more cost effective,” Theage.com.au quoted Dr Niall Tebbutt, medical oncologist from the Austin Hospital in Melbourne and Australian investigator in the study, as saying.
While current treatments fail to cure advanced bowel cancer cannot, new targeted therapies that have been introduced in the markets have shown that promise in lengthening survival and improving quality of life.
Erbitux works by locking onto a specific growth protein in the tumour and switching off overactive chemical signals in cancer cells and hence blocking any kind of instructions from reaching it so that it does not grow or spread. While the drug is available in Australia for use when other therapies have failed, but its still not subsidised and thus remains out of reach for most.
Australian oncologists say that the test for the gene is available now but is of “limited benefit” until the drug is awarded a subsidy, the chances of which are boosted on the back of the new results,
Professor Ian Olver, Cancer Council Australia chief, said that the development showed promising results for patients diagnosed with advanced disease, a common occurrence as the cancer has few visible symptoms.
“Ideally, though, we should be catching the disease earlier with bowel screening,” said Professor Olver.
The trail also found that those having normal form of the gene had a 32 percent lower risk of disease progression when they added the new biological drug to their treatment.
The results were presented at the American Society of Clinical Oncology meeting in Chicago . (ANI)
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- New Therapy can ease irritable bowels - Jul 19, 2011
- Scientists stumble upon 'stop cancer' gene - Nov 16, 2011
- 'Harmless' soil bacteria can help kill tumours - Sep 05, 2011
- 'Wonderdrug' keeps breast cancer away - Feb 25, 2011
- New drug shows promise against ovarian and breast cancer - Aug 13, 2010
- Intestinal stem cells offer clues to colon cancer origin and relapse - Mar 18, 2011
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
- Pill to fight deadly skin cancer in sight - Jan 20, 2011
- India witnessing rise in pancreatic cancer, say doctors - Oct 06, 2011
- 'Smart' new drug shows promise in ovarian cancer - Nov 09, 2010
- Skin cancer pill showing 'remarkable' results, say researchers - Aug 26, 2010
- Genetic changes make cancer deadly - Mar 08, 2012
- Wonder drug could kill all types of cancer - Jun 27, 2011
- Genes linked to aggressive breast cancer identified - Aug 17, 2010
Tags: australians, bowel cancer, cancer bowel, cancer cells, cancer drugs, cancer patients, chemical signals, chemotherapy, costly drug, drug therapies, erbitux, gene test, genetic test, improving quality, medical oncologist, oncologists, pharmaceutical benefits scheme, theage, tumour, tumours